AstraZeneca's oral GLP-1 elecoglipron cut weight up to 10.5% in Phase 2, as AZ launches multiple Phase 3 trials targeting a $5B obesity franchise.
The race to be third to market with an obesity pill has a number of contenders, including Roche, Pfizer and Structure Therapeutics. On Monday, AstraZeneca …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how…
AstraZeneca publie des résultats prometteurs pour son traitement oral contre l’obésité, elecoglipron, ouvrant la voie à un nouvel…
Especialistas consideran que el medicamento merece evaluaciones más amplias antes de solicitar su autorización
Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and…
Swiss pharmaceutical firm Roche is investing billions in new obesity treatments in hopes of breaking into a highly competitive…
Doentes perderam 10,5% do peso em 26 semanas num ensaio intermédio da pílula experimental da AstraZeneca, que quer disputar o…
